Is notch signaling a specific target in hepatocellular carcinoma?

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 7, 2015, Pages 809-815

  Sun, Lichun ^a,b   Sun, Guangchun ^a   Yu, Yan ^a   Coy, David H ^b  

^a FUDAN UNIVERSITY   (China)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Hepatocellular carcinoma; Notch signaling; Oncogene; Therapeutics; Tumor suppressor

Indexed keywords

CURCUMIN; DOXORUBICIN; NOTCH RECEPTOR; SMALL INTERFERING RNA; SORAFENIB; VALPROIC ACID; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CYTOTOXICITY; DOWN REGULATION; HUMAN; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; GENE SILENCING; GENE THERAPY; GENETICS; LIVER NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DOXORUBICIN; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; VALPROIC ACID;

EID: 84938682383     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150202102809     Document Type: Article

References (54)

1. Morell, C.M.; Strazzabosco, M. Notch signaling and new therapeutic options in liver disease. J. Hepatol., 2014, 60(4), 885- 890.
2. Bogaerts, E.; Heindryckx, F.; Vandewynckel, Y.P.; Van Grunsven, L.A.; Van Vlierberghe, H. The roles of transforming growth factor- β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours. Int. J. Oncol., 2014, 44(4), 1015-1022
3. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics. CA Cancer J. Clin., 2014, 64(1), 9-29.
4. Mittal, S.; El-Serag, H.B. Epidemiology of hepatocellular carcinoma: Consider the population. J. Clin. Gastroenterol., 2013, 47 Suppl, S2-6.
5. El-Serag, H.B. Current concepts: Hepatocellular carcinoma. N. Engl. J. Med., 2011, 365, 1118-1127.
6. Fan, J.; Wang, Z. Progress in comprehensive treatment of primary liver cancer. Int. J. Dig. Dis., 2013, 33, 73-76.
7. Zeng, H.; Chen, W. Cancer epidemiology and control in China: State of the art. Prog. Chemistry, 2013, 25, 1415-1420.
8. El-Serag, H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 2012, 142, 1264-1273.
9. Shlomai, A.; De Jong, Y.P.; Rice, C.M. Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma. Semin. Cancer Biol., 2014, 26, 78-88.
10. Tanaka, M.; Katayama, F.; Kato, H.; Tanaka, H.; Wang, J.; Qiao, Y.L.; Inoue, M. Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures. J. Epidemiol., 2011, 21, 401-416.
11. Villanueva, A.; Llovet, J.M. Liver ancer in 2013: Mutational landscape of HCC-the end of the beginning. Nat. Rev. Clin. Oncol., 2014, 25(2),196-209.
12. Moeini, A.; Cornella, H.; Villanueva, A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer, 2012, 1, 83-93.
13. Morell, C.M.; Fiorotto, R.; Fabris, L.; Strazzabosco, M. Notch signalling beyond liver development: Emerging concepts in liver repair and oncogenesis. Clin. Res. Hepatol. Gastroenterol., 2013, 37, 447-454.
14. Noh, J.H.; Bae, H.J.; Eun, J.W.; Shen, Q.; Park, S.J.; Kim, H.S.; Nam, B.; Shin, W.C.; Lee, E.K.; Lee, K.B.; Jang, J.J.; Park, W.S.; Lee, J.Y.; Nam, S.W. HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Cancer Res., 2014, 74(6), 1728-1738.
15. Venturelli, S.; Berger, A.; Bocker, A.; Busch, C.; Weiland, T.; Noor, S.; Leischner, C.; Schleicher, S.; Mayer, M.; Weiss, T.S.; Bischoff, S.C.; Lauer, U.M.; Bitzer, M. Resveratrol as a pan- HDAC inhibitor alters the acetylation status of jistone proteins in human-derived hepatoblastoma cells. PLoS One, 2013, 8, e73097.
16. Wu, L.; Aster, J.C.; Blacklow, S.C.; Lake, R.; Artavanis-Tsakonas, S.; Griffin, J.D. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat. Genet., 2000, 26, 484-489.
17. Kunnimalaiyaan, M.; Chen, H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist, 2007, 12, 535-542.
18. Wu, L.; Griffin, J.D. Modulation of notch signaling by mastermindlike (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin. Cancer Biol., 2004, 14, 348-356.
19. Han, J.; Hendzel, M.J.; Allalunis-Turner, J. Notch signaling as a therapeutic target for breast cancer treatment? Breast Cancer Res., 2011, 13(3), 210.
20. Bray, S.J. Notch signalling: A simple pathway becomes complex. Nat. Rev. Mol. Cell Biol., 2006, 7, 678-689.
21. Yin, L.; Velazquez, O.C.; Liu, Z.J. Notch signaling: Emerging molecular targets for cancer therapy. Biochem. Pharmacol., 2010, 80, 690-701.
22. Sjolund, J.; Manetopoulos, C.; Stockhausen, M.T.; Axelson, H. The Notch pathway in cancer: Differentiation gone awry. Eur. J. Cancer, 2005, 41, 2620-2629.
23. Giovannini, C.; Baglioni, M.; Toaldo, B.M.; Ventrucci, C.; D'Adamo, S.; Cipone, M.; Chieco, P.; Gramantieri, L.; Bolondi, L. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget, 2013, 4, 1618-1631.
24. Giovannini, C.; Gramantieri, L.; Chieco, P.; Minguzzi, M.; Lago, F.; Pianetti, S.; Ramazzotti, E.; Marcu, K.B.; Bolondi, L. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J. Hepatol., 2009, 50, 969-979.
25. Weng, A.P.; Aster, J.C. Multiple niches for Notch in cancer: Context is everything. Curr. Opin. Genet. Dev., 2004, 14, 48-54.
26. Dotto, G.P. Notch tumor suppressor function. Oncogene, 2008, 27, 5115-5123.
27. Kunnimalaiyaan, M; Traeger, K; Chen, H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 289, G636-642.
28. Leong, K.G.; Karsan, A. Recent insights into the role of Notch signaling in tumorigenesis. Blood, 2006, 107, 2223-2233.
29. Koch, U.; Radtke, E. Notch and cancer: A double-edged sword. Cell. Mol. Life Sci., 2007, 64, 2746-2762.
30. Mungamuri, S.K.; Yang, X.; Thor, A.D.; Somasundaram, K. Survival signaling by Notch1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res., 2006, 66, 4715- 4724.
31. Geisler, F; Strazzabosco, M. Emerging roles of Notch signaling in liver disease. Hepatology. 2015, 61(1),382-392.
32. Dill, M.T.; Tornillo, L.; Fritzius, T.; Terracciano, L.; Semela, D.; Bettler, B.; Heim, M.H.; Tchorz, J.S. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology, 2013, 57, 1607-1619.
33. Ahn, S.; Hyeon, J.; Park, C.K. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int., 2013, 12, 286-294.
34. Ning, L.; Wentworth, L.; Chen, H.; Weber, S.M. Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am. J. Transl. Res., 2009, 1, 358-366.
35. Villanueva, A.; Alsinet, C.; Yanger, K.; Hoshida, Y.; Zong, Y.; Toffanin, S.; Rodriguez-Carunchio, L.; Sole, M.; Thung, S.; Stanger, B.Z.; Llovet, J.M. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology, 2012, 143, 1660-1669.
36. Gramantieri, L.; Giovannini, C.; Lanzi, A.; Chieco, P.; Ravaioli, M.; Venturi, A.; Grazi, G.L.; Bolondi, L. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int., 2007, 27, 997-1007.
37. Hu, L.; Xue, F.; Shao, M.; Deng, A.; Wei, G. Aberrant expression of Notch3 predicts poor survival for hepatocellular carcinomas. Biosci. Trends, 2013, 7(3), 152-156.
38. Wang, F.; Zhou, H.; Yang, Y.; Xia, X.; Sun, Q.; Luo, J.; Cheng, B. Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol. Rep., 2012, 27, 1170-1176.
39. Gao, J.; Dong, Y.; Zhang, B.; Xiong, Y.; Xu, W.; Cheng, Y.; Dai, M.; Yu, Z.; Xu, H.; Zheng, G. Notch1 activation contributes to tumor cell growth and proliferation in human hepatocellular carcinoma HepG2 and SMMC7721 cells. Int. J. Oncol., 2012, 41, 1773-81.
40. Viatour, P.; Ehmer, U.; Saddic, L.A.; Dorrell, C.; Andersen, J.B.; Lin, C.; Zmoos, A.F.; Mazur, P.K.; Schaffer, B.E.; Ostermeier, A.; Vogel, H.; Sylvester, K.G.; Thorgeirsson, S.S.; Grompe, M.; Sage, J. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J. Exp. Med., 2011, 208, 1963-1976.
41. Qi, R.; An, H.; Yu, Y.; Zhang, M.; Liu, S.; Xu, H.; Guo, Z.; Cheng, T.; Cao, X. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res., 2003, 63, 8323-8329.
42. Wang, C.; Qi, R.; Li, N.; Wang, Z.; An, H.; Zhang, Q.; Yu, Y.; Cao, X. Notch1 signaling sensitizes tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. J. Biol. Chem., 2009, 284, 16183-16190.
43. Liu, Y.; Xing, ZB.; Wang, S.Q.; Chen, S.; Liu, Y.K.; Li, Y.H.; Li, Y.F.; Wang, Y.Q.; Lu, Y.; Hu, W.N.; Zhang, J.H. MDM2-MOFH4K16ac axis contributes to tumorigenesis induced by Notch. FEBS J., 2014, 281(15),3315-3324.
44. Giovannini, C.; Gramantieri, L.; Minguzzi, M.; Fornari, F.; Chieco, P.; Grazi, G.L.; Bolondi, L. CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma. Am. J. Pathol., 2012, 181, 413-422.
45. Wang, H.; Chen, G.; Wang, H.; Liu, C. RITA inhibits growth of human hepatocellular carcinoma through induction of apoptosis. Oncol. Res., 2013, 20(10), 437-445.
46. Aihara, A.; Huang, C.K.; Olsen, M.J.; Lin, Q.; Chung, W.; Tang, Q.; Dong, X.; Wands, J.R. A Cell surface β -Hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology, 2014, 60(4), 1302-1313.
47. Zhang, S.; Yang, Y.; Liang, Z.; Duan, W.; Yang, J.; Yan, J.; Wang, N.; Feng, W.; Ding, M.; Nie, Y.; Jin, Z. Silybin-mediated inhibition of notch signaling exerts antitumor activity in human hepatocellular carcinoma cells. PLoS One, 2013, 8, e83699.
48. Tatebe, H.; Shimizu, M.; Shirakami, Y.; Sakai, H.; Yasuda, Y.; Tsurumi, H.; Moriwaki, H. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett., 2009, 285, 210-217.
49. Machado, M.C.; Bellodi-Privato, M.; Kubrusly, M.S. Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. J. Exp. Ther. Oncol., 2011, 9, 85-92.
50. Li, X.; Zhu, Y.; He, H.; Lou, L.; Ye, W.; Chen, Y.; Wang, J. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells. Biochem. Biophys. Res. Commun., 2013, 436, 259-264.
51. Weiller, M.; Weiland, T.; Dunstl, G.; Sack, U.; Kunstle, G.; Wendel, A. Differential immunotoxicity of histone deacetylase inhibitors on malignant and naive hepatocytes. Exp. Toxicol. Pathol., 2011, 63, 511-517.
52. Armeanu, S.; Pathil, A.; Venturelli, S.; Mascagni, P.; Weiss, T.S.; Gottlicher, M.; Gregor, M.; Lauer, U.M.; Bitzer, M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J. Hepatol., 2005, 42, 210-217.
53. Ye, C.G.; Chen, G.G.; Ho, R.L.; Merchant, J.L.; He, M.L.; Lai, P.B. Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma. Biochim. Biophys. Acta, 2013, 1833, 2970-2979.
54. Matsuda, Y.; Wakai, T.; Kubota, M.; Osawa, M.; Hirose, Y.; Sakata, J.; Kobayashi, T.; Fujimaki, S.; Takamura, M.; Yamagiwa, S.; Aoyagi, Y. Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma. Int. J. Clin. Exp. Pathol., 2014, 7(4), 1299-1313.